Usually, endocrine therapy remains the core adjuvant therapy for most of the early breast cancer patients who are diagnosed as ER+, while chemotherapy is recommended as the first-line systemic adjuvant modality for most HER2+ and triple-negative breast cancer patients [6]. This evidence concerns the gene ERBB2 and breast carcinoma.